Even though Advair’s main patent expired in 2010 and the patent on the Diskus inhaler expired in 2016, until now no-one has managed to get the FDA to approve a cheaper copy of the drug-device ...
Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount ... while the patent on GSK’s Diskus inhaler expired in 2016.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback